Equities research analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report sales of $1.59 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the highest sales estimate coming in at $1.7 million and the lowest estimate coming in at $1.46 million. ZIOPHARM Oncology posted sales of $1.7 million in the same quarter last year, which suggests a negative year-over-year growth rate of 6.5%. The business is expected to announce its next earnings results on Tuesday, August 8th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full year sales of $1.59 million for the current year, with estimates ranging from $5.99 million to $7 million. For the next financial year, analysts expect that the company will post sales of $5.62 million per share, with estimates ranging from $3 million to $8 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, May 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.71 million. ZIOPHARM Oncology had a negative net margin of 2,276.89% and a negative return on equity of 364.49%. The business’s revenue for the quarter was down 18.8% compared to the same quarter last year.
ZIOP has been the subject of a number of recent research reports. Griffin Securities reissued a “buy” rating and set a $23.00 price target on shares of ZIOPHARM Oncology in a research report on Tuesday, February 28th. Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a research report on Thursday, January 12th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of ZIOPHARM Oncology in a research report on Thursday, January 12th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. ZIOPHARM Oncology has an average rating of “Hold” and a consensus price target of $10.25.
TRADEMARK VIOLATION NOTICE: “$1.59 Million in Sales Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/05/10/1-59-million-in-sales-expected-for-ziopharm-oncology-inc-ziop-this-quarter.html.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) traded down 2.795% during mid-day trading on Wednesday, reaching $6.503. 223,558 shares of the company traded hands. ZIOPHARM Oncology has a 52 week low of $4.45 and a 52 week high of $8.72. The firm has a 50-day moving average price of $6.72 and a 200 day moving average price of $6.33. The firm’s market capitalization is $849.95 million.
Several large investors have recently modified their holdings of the company. Third Security LLC purchased a new stake in shares of ZIOPHARM Oncology during the fourth quarter worth approximately $51,946,000. Norges Bank purchased a new stake in shares of ZIOPHARM Oncology during the fourth quarter worth approximately $5,556,000. Iridian Asset Management LLC CT purchased a new stake in shares of ZIOPHARM Oncology during the first quarter worth approximately $1,187,000. Glacier Peak Capital LLC purchased a new stake in shares of ZIOPHARM Oncology during the fourth quarter worth approximately $364,000. Finally, Michael & Susan Dell Foundation purchased a new stake in shares of ZIOPHARM Oncology during the fourth quarter worth approximately $357,000. 41.26% of the stock is currently owned by institutional investors and hedge funds.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.